Editorials |
From the Department of Medicine, Rheumatology Section, VA Health Care System/UCSD, San Diego, Calif.
Correspondence to Robert Terkeltaub, MD, VA Medical Center, Rheumatology, 3350 La Jolla Village Drive, San Diego, CA 92161. E-mail rterkeltaub{at}ucsd.edu
Key Words: arterial calcification RANKL osteoprotegerin BMP2 smooth muscle cell
| Introduction |
|---|
|
|
|---|
See accompanying article on page 2158
In a study published in the current issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Preusch et al report the effects of lineage-specific deletion of the glucocorticoid receptor (GR) in bone marrow-donor macrophages on chondro-osseous differentiation and calcification in dietary-induced atherosclerotic lesions in lethally irradiated, bone marrow transplant recipient, LDLR knockout mice.6 Arterial calcification appears to be an active and organized multicellular process, which is switched on by chondro-osseous differentiation of a variety of progenitors in the artery wall, and regulated in part by systemic influences. Such influences include the effects of calciotropic hormones and of mineral nucleation promoters and inhibitors.1–4 In the intralesional intercellular dialogue that drives vascular calcification, potential progenitors of calcifying osteoblastic and chondrocytic cells include not only pericytes and resident and recruited vascular stem cells, but also nonterminally differentiated phenotypically plastic adventitial myofibroblasts and smooth muscle cells (SMCs). Significantly, the latter may undergo chondro-osseous transdifferentiation.1–5,7–12
Intralesional mechanisms that drive chondro-osseous differentiation in arterial calcification include an excess of inducers of chondro-osseous commitment and maturation, such as BMP2, inorganic phosphate (Pi) generation and uptake by SMCs, and signaling stimulated by the wnt βcatenin axis and by transglutaminase 2.1–5,7–12 Conversely, intralesional deficiency of physiological inhibitors of chondro-osseous differentiation also plays a role in arterial calcification, as exemplified by the linkage of spontaneous intraarterial chondrogenesis and calcification with paucity of the BMP2 inhibitor and matrix calcification inhibitor MGP,13 or of the chondrogenic and matrix calcification inhibitor PPi.9,14
| Paracrine Effects of Macrophage-Driven Inflammation in Arterial Calcification |
|---|
|
|
|---|
turns on myofibroblast transdifferentiation via oxidative stress and wnt β-catenin signals.2,7 Inflammation-modulated increases in matrix metalloproteinase (MMP) activity and alterations in extracellular matrix collagen I, elastin,16,17 and osteopontin3,8 can equally promote calcification of arterial extracellular matrix. | Addressing GR Signaling in Arterial Calcification |
|---|
|
|
|---|
Importantly, Preusch et al demonstrated that recipients transplanted with macrophage lineage GR-deficient bone marrow showed decreased expression not only of certain chondrocyte lineage-specific genes, but also of BMP2 and Msx2, in atherosclerotic lesions. The homeodomain transcription factor, Msx2, is involved in development and was recently implicated downstream of BMP2 in mediating ectopic osteoblastic differentiation during arterial calcification.2,7 An additional unexpected finding in the study of Preusch et al concerns the observation that GR ligand treatment of a macrophage cell line induced a paracrine stimulatory effect of macrophage-conditioned medium on Pi-stimulated calcification in cultured SMCs.6 GR signaling in pericytes and SMCs is known to promote chondro-osseous differentiation and calcification, an effect which is partly mediated by suppression of both MGP and osteopontin expression in pericytes.20
The Figure highlights the possible relationship between the above findings on GR signaling and the recognized intercellular dialogue between macrophages and SMCs; this dialogue promotes chondro-ossous transdifferentiation of SMCs and arterial calcification. One may speculate that paracrine effects of macrophage GR signaling that drive calcification may be partly mediated by GR signaling-induced apoptosis in monocyte/macrophages,21 especially as apoptosis can promote calcification by effects that include release of apoptotic bodies with precipitatation of hydroxyapatite.22 In addition, it is noteworthy that GR signaling in osteoblasts induces Receptor Activator for Nuclear Factor-
B Ligand (RANKL).
|
| Macrophage GR Signaling Regulates RANKL in Arterial Calcification |
|---|
|
|
|---|
Induction of RANKL by GR signaling, superimposed on GR suppression of osteoblast function, contributes to GR-induced osteoporosis.28 It has not been determined as yet whether macrophage lineage GR expression, (via modulation of osteoclast development and bone turnover), might influence longer-range bone-vascular axis communication loops in arterial calcification (eg, by alterations in calciotropic hormones, by vascular cell expression of calcium-sensing, PTH and vitamin D receptors and the vitamin D receptor modulator TIF1
, and possibly by release of circulating regulators of mineral nucleation from bone). In addition, Preusch et al focused on ectopic chondrogenic differentiation, which appears central to atherosclerotic calcification in apoE knockout mice.6,25 Though chondrogenesis may be limited in uncalcified and calcified human atherosclerotic lesions,29 chondrocyte-specific gene expression is detected in some forms of calcification of human arterial tunica media.10 Nevertheless, ectopic osteoblastic differentiation is fundamental to other forms of arterial calcification in mice and humans.1–4
| Conclusions |
|---|
|
|
|---|
) participate in the short-distance and long-distance communication loops between inflammation, oxidative stress, bone metabolism, and arterial calcification may hold the key to the development of novel therapeutics for inhibition of both osteoporosis and vascular calcification. For the moment, the work of Preusch et al encourages definitive investigation of the net effects of both endogenous and synthetic glucocorticoids on phenotypes of human vascular calcification. | Acknowledgments |
|---|
This work was supported by the VA Research Service and NIH (HL077360, HL087252).
Disclosures
None.
| References |
|---|
|
|
|---|
2. Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol. 2006; 26: 1423–1430.
3. El-Abbadi M, Giachelli CM. Mechanisms of vascular calcification. Adv Chronic Kidney Dis. 2007; 14: 54–66.[CrossRef][Medline] [Order article via Infotrieve]
4. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004; 24: 1161–1170.
5. Moura LM, Maganti K, Puthumana JJ, Rocha-Gonçalves F, Rajamannan NM. New understanding about calcific aortic stenosis and opportunities for pharmacologic intervention. Curr Opin Cardiol. 2007; 22: 572–577.[Medline] [Order article via Infotrieve]
6. Preusch MR, Rattazzi M, Albrecht C, Merle U, Tuckermann J, Schütz G, Blessing G, Zoppelaro G, Pauletto P, Krempien R, Rosenfeld ME, Katus HA, Bea F Critical role of marophages in glucocorticoid driven vascular calcification in a mouse model of atherosclerosis. Arterisocelr Thromb Vasc Biol. 2008; 28: 2158–2164.[CrossRef]
7. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, Cheng SL, Towler DA. Aortic Msx2-Wnt calcification cascade is regulated by TNF-alpha-dependent signals in diabetic Ldlr–/– mice. Arterioscler Thromb Vasc Biol. 2007; 27: 2589–2596.
8. Johnson KA, Polewski M, Terkeltaub RA. Transglutaminase 2 is central to induction of the arterial calcification program by smooth muscle cells. Circ Res. 2008; 102: 529–537.
9. Johnson K, Polewski M, van Etten D, Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1–/– mice. Arterioscler Thromb Vasc Biol. 2005; 25: 686–691.
10. Neven E, Dauwe S, De Broe ME, D'Haese PC, Persy V. Endochondral bone formation is involved in media calcification in rats and in men. Kidney Int. 2007; 72: 574–581.[CrossRef][Medline] [Order article via Infotrieve]
11. Fukagawa M, Kazama JJ. The making of a bone in blood vessels: from the soft shell to the hard bone. Kidney Int. 2007; 72: 533–534.[CrossRef][Medline] [Order article via Infotrieve]
12. Aikawa E, Nahrendorf M, Figueiredo JL, Swirski FK, Shtatland T, Kohler RH, Jaffer FA, Aikawa M, Weissleder R. Osteogenesis associates with inflammation in early-stage atherosclerosis evaluated by molecular imaging in vivo. Circulation. 2007; 116: 2841–2850.
13. El-Maadawy S, Kaartinen MT, Schinke T, Murshed M, Karsenty G, McKee MD Cartilage formation and calcification in arteries of mice lacking matrix Gla protein. Connect Tissue Res. 2003; 44 Suppl 1: 272–278.[CrossRef][Medline] [Order article via Infotrieve]
14. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Höhne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A, McGill J, Filippone M, Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M, Terkeltaub R, Nürnberg P. Mutations in ENPP1 are associated with idiopathic infantile arterial calcification. Nat Genet. 2003; 34: 379–381.[CrossRef][Medline] [Order article via Infotrieve]
15. Parhami F, Morrow AD, Balucan J, Leitinger N, Watson AD, Tintut Y, Berliner JA, Demer LL. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol. 1997; 17: 680–687.
16. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC, Vyavahare NR. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation. 2004; 110: 3480–3487.
17. Qin X, Corriere MA, Matrisian LM, Guzman RJ. Matrix metalloproteinase inhibition attenuates aortic calcification. Arterioscler Thromb Vasc Biol. 2006; 26: 1510–1516.
18. Joyce DA, Gimblett G, Steer JH. Targets of glucocorticoid action on TNF-alpha release by macrophages. Inflamm Res. 2001; 50: 337–340.[CrossRef][Medline] [Order article via Infotrieve]
19. Asai K, Funaki C, Hayashi T, Yamada K, Naito M, Kuzuya M, Yoshida F, Yoshimine N, Kuzuya F. Dexamethasone-induced suppression of aortic atherosclerosis in cholesterol-fed rabbits. Possible mechanisms. Arterioscler Thromb. 1993; 13: 892–899.
20. Kirton JP, Wilkinson FL, Canfield AE, Alexander MY. Dexamethasone downregulates calcification-inhibitor molecules and accelerates osteogenic differentiation of vascular pericytes: implications for vascular calcification. Circ Res. 2006; 98: 1264–1272.
21. Amsterdam A, Sasson R. The anti-inflammatory action of glucocorticoids is mediated by cell type specific regulation of apoptosis. Mol Cell Endocrinol. 2002; 189: 1–9.[CrossRef][Medline] [Order article via Infotrieve]
22. Kirsch T, Wang W, Pfander D. Functional differences between growth plate apoptotic bodies and matrix vesicles. J Bone Miner Res. 2003; 18: 1872–1881.[CrossRef][Medline] [Order article via Infotrieve]
23. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998; 12: 1260–1268.
24. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008; 473: 139–146.[CrossRef]
25. Bennett BJ, Scatena M, Kirk EA, Rattazzi M, Varon RM, Averill M, Schwartz SM, Giachelli CM, Rosenfeld ME. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE–/– mice. Arterioscler Thromb Vasc Biol. 2006; 26: 2117–2124.
26. Morony S, Tintut Y, Zhang Z, Cattley RC, Van G, Dwyer D, Stolina M, Kostenuik PJ, Demer LL. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(–/–) mice. Circulation. 2008; 117: 411–420.
27. Kaden JJ, Dempfle CE, Kiliç R, Sarikoç A, Hagl S, Lang S, Brueckmann M, Borggrefe M. Influence of receptor activator of nuclear factor kappa B on human aortic valve myofibroblasts. Exp Mol Pathol. 2005; 78: 36–40.[CrossRef][Medline] [Order article via Infotrieve]
28. Rehman Q, Lane NE. Effect of glucocorticoids on bone density. Med Pediatr Oncol. 2003; 41: 212–216.[CrossRef][Medline] [Order article via Infotrieve]
29. Aigner T, Neureiter D, Câmpean V, Soder S, Amann K. Expression of cartilage-specific markers in calcified and non-calcified atherosclerotic lesions. Atherosclerosis. 2008; 196: 37–41.[CrossRef][Medline] [Order article via Infotrieve]
Related Article:
Arterioscler Thromb Vasc Biol 2008 28: 2158-2164.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2008 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |